Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine Progressing Normality
January 21, 2026
Source: drugdu
31
Securities Daily Online, Jan 20 (Reporter) — Olymvax Biopharmaceuticals stated during an investor survey that the Phase III clinical trial of the company's recombinant Staphylococcus aureus vaccine is proceeding as planned. As of now, the study remains blinded, and no efficacy data has been generated yet.
The company expects to complete the initial and confirmatory testing of all serum samples in the first quarter of this year (2026). Meanwhile, data cleaning is currently underway. It is anticipated that after completing data cleaning and obtaining the serum test reports in the first half of this year, the company will be able to perform a periodic database lock and the first unblinding for protective efficacy analysis.
As vaccine clinical trials are susceptible to various factors, the final progress and results of the clinical trials shall be subject to the company's official public disclosures.
https://finance.eastmoney.com/a/202601203624958315.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Its drug marketing application for injectable iza-bren has been accepted January 21, 2026
- Kain Technology withdrew a drug registration application, resulting in a profit reduction of 111 million yuan in 2025 January 21, 2026
- Received Notice of Approval for Drug Clinical Trial January 21, 2026
- Breaking news! AstraZeneca to be delisted from Nasdaq. January 21, 2026
- XinYue Bio Secures Tens of Millions in Series A+ Follow-on Funding to Advance DEL+AI-Powered Drug Discovery January 21, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
